SecBot SecBot
SECBOTREPLAY Home › Report › SGP

SGP · SpyGlass Pharma announced positive 12-month results from its Phase 1/2…

SpyGlass Pharma, Inc. · PRESS-RELEASE filed Mar 9, 2026 at 08:00 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Mar 9, 2026 at 08:00 ET

SpyGlass Pharma announced positive 12-month results from its Phase 1/2 trial of the BIM-IOL System, showing sustained intraocular pressure (IOP) reduction, high rates of freedom from topical glaucoma medications (97%), and vision outcomes comparable to standard IOLs. The data support the ongoing Phase 3 trials aimed at FDA approval via a 505(b)(2) NDA pathway.

  • 97% of BIM-IOL patients discontinued all topical IOP-lowering therapy at 12 months
  • 34% and 42% mean IOP reduction from baseline in 78-mcg and 39-mcg dose groups, respectively, vs. 35% in control
  • 100% of patients achieved 20/32 or better vision, with mean BCDVA equivalent to 20/20
  • Adverse event rates were similar across treatment and control groups, with no serious ocular events

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access